BTKi Combo Strong Option in CLL BTKi Combo Strong Option in CLL
A new interim analysis finds more evidence that ibrutinib plus rituximab is a viable option for younger patients with untreated chronic lymphocytic leukemia compared with standard chemoimmunotherapy.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia | Rituxan